Omicron

In COVID-19 clinical update #105, Daniel Griffin discusses changes in brain structure after infection, dementia in patients with pneumonia, Paxlovid in children, mask effectiveness in schools, host factors and severe disease, post-acute symptoms, and the mission of CEPI. Click arrow to playDownload TWiV 874 (49 MB .mp3, 41 min)Subscribe (free): Apple Podcasts, Google Podcasts, RSS, email Become a patron of TWiV! Show notes …

TWiV 874: COVID-19 clinical update #105 with Dr. Daniel Griffin Read More »

TWiV discusses whether or not Omicron should be designated a new serotype of SARS-CoV-2, and the finding that amino acid changes that adapt SARS-CoV-2 to mink or ferret do not increase fitness in the human airway.

In COVID-19 clinical update #103, Daniel Griffin covers immunocompromised people, hospitalization of children, vaccine usage update, Omicron and cross-reactive neutralizing antibodies, reinfection prevents disease in hamsters, repeated infections with endemic coronaviruses, global burden of antimicrobial resistance, ivermectin not protective in hamsters, and Omicron evades therapeutic monoclonals. Click arrow to playDownload TWiV 870 (52 MB .mp3, 43 …

TWiV 870: COVID-19 clinical update #103 with Dr. Daniel Griffin Read More »

Nels joins TWiV to discuss hypotheses for the origins of Omicron, including that it came from mice or arose during chronic infection of an immunocompromised patient. Hosts: Vincent Racaniello, Rich Condit, Kathy Spindler, and Brianne Barker Guest: Nels Elde Click arrow to playDownload TWiV 861 (69 MB .mp3, 114 min)Subscribe (free): Apple Podcasts, Google Podcasts, RSS, email Become a patron of TWiV! Show notes …

TWiV 861: Rough draft of Omicron origins Read More »

In COVID-19 clinical update #99, Daniel Griffin discusses Omicron disease severity, neurologic manifestations in children, testing outcomes during multiple infections, boosters improve VE and VD, booster efficacy for ED and UC encounters, vaccines induce cross-protective T cell memory, and indications for monoclonal antibody therapy.